|
|
Article: Data Show That LUNESTA(TM) May Be Cost Effective for Treating Chronic Insomnia.
- Article from:
- PR Newswire
- Article date:
- May 17, 2005
|
Copyright informationCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MARLBOROUGH, Mass., May 17 /PRNewswire-FirstCall/ -- Sepracor Inc. announces the presentation of results from two analyses designed to assess potential pharmacoeconomic benefits associated with the use of LUNESTA(TM) brand eszopiclone in the long-term treatment of insomnia. LUNESTA is the first and only sleep aid approved by the U.S. Food and Drug Administration (FDA) for long-term use. These data were presented yesterday at the 10th Annual International Society for Pharmacoeconomics and Outcomes Research Meeting (ISPOR) held in Washington, DC.
Forecasting the Impact of Adding a New Drug on Formulary Using Medical Claims Data and Clinical Literature: A Case Study of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Citrix Touts GoToMeeting's Cost Effectiveness
Wireless News;
December 13, 2008 ;
539 words
...Citrix Touts GoToMeeting's Cost Effectiveness WIRELESS NEWS-December 13, 2008-Citrix Touts GoToMeeting's Cost Effectiveness (C)2008 10Meters - http://www.10meters.com With the global economy officially in recession, companies are trying to...
|
|